<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096742</url>
  </required_header>
  <id_info>
    <org_study_id>Altreno-2019-01</org_study_id>
    <nct_id>NCT04096742</nct_id>
  </id_info>
  <brief_title>Altreno for Chest Rejuvenation</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Vehicle-controlled Study Evaluating the Efficacy, Safety and Patient Satisfaction of Tretinoin 0.05% Lotion (Altreno) for Chest Rejuvenation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, double-blind, randomized, vehicle-controlled study to
      evaluate the efficacy, safety and patient satisfaction of tretinoin 0.05% lotion (Altreno)
      for chest rejuvenation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center, prospective, double-blind, randomized, vehicle-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Quality</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Nine-point scale to assess skin quality for the appearance of crepiness, coarse lines/wrinkles, skin texture, and skin tone evenness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Fabi-Bolton Wrinkle Scale (FBWS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Investigator Percent Improvement Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Investigator Global aesthetic improvement scale (I-GAIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Subject Global aesthetic improvement scale (S-GAIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Patient satisfaction score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments</measure>
    <time_frame>Month 6</time_frame>
    <description>End of study patient questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Photodamaged Skin</condition>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>Altreno</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tretinoin 0.05% lotion (Altreno)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vehicle lotion not containing tretinoin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin 0.05% lotion (Altreno)</intervention_name>
    <description>Altreno topical lotion</description>
    <arm_group_label>Altreno</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Lotion not containing active ingredient (tretinoin)</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females or males age 18-65, Fitzpatrick skin types I-VI

          2. Moderate to severe photodamage (Fitzpatrick Wrinkle score of 4-9)

          3. Willingness and ability to provide written informed consent and HIPAA authorization
             prior to performance of any study-related procedures.

          4. Willingness to abstain from any other procedures to the areas to be treated throughout
             the trial period.

          5. Willingness and ability to comply with protocol requirements, including adherence to
             photography and returning for follow-up visits.

          6. Women of childbearing potential willing to use an acceptable form of birth control
             during trial period.

               1. Hormonal contraception - pill, injection, implant, patch, vaginal ring,
                  Intrauterine device

               2. Intrauterine coil

               3. Barrier method used with an additional form of contraception (e.g., sponge,
                  spermicide or condom)

               4. Abstinence (If practicing abstinence must agree to use barrier method described
                  above (c) if becomes sexually active).

               5. Vasectomized partner (Must agree to use barrier method described above (c) if
                  becomes sexually active with an Un-Vasectomized partner).

          7. Female patients will be either of non-childbearing potential defined as: Having no
             uterus and/or both ovaries, postmenopausal (no menses for at least 12 months prior),
             or has had a bilateral tubal ligation at least 6 months prior to study enrollment.

        Exclusion Criteria:

          1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the
             trial.

          2. Known hypersensitivity or allergy to the components of the study medication.

          3. Concurrent enrollment in any study involving the use of investigational devices or
             drugs.

          4. Current smoker or history of smoking in the last five years.

          5. Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum,
             nicotine patches, etc.

          6. Presence of an active systemic or local skin disease that may affect treatment area.

          7. History of prior surgery to the treatment area

          8. History of prior significant trauma to the chest

          9. History of the following cosmetic treatments to the area(s) to be treated:

               1. Energy based device or laser procedure to the chest within the past 6 months
                  (Ultherapy, ablative and non-ablative laser, intense pulsed light, etc)

               2. Injectable filler of any type to the chest in the past 2 years (Hyaluronic acid
                  fillers (Voluma, Belotero), Poly-L-Lactic acid fillers (e.g. Sculptra), and CaHA
                  fillers (e.g. Radiesse)

               3. Ever for permanent fillers (e.g. Silicone, ArteFill)

         10. Surgical dermabrasion or chemical peels in the treatment area within the past 6 month

         11. Any planned surgical intervention to the chest for the duration of the trial

         12. Any visible surface alteration to the chest that may interfere with evaluation, at
             investigator discretion

         13. Any pre-existing medical condition that may interfere with study compliance or
             evaluation, at investigator discretion

         14. Inability to comply with all study protocols and regulations

         15. Current taking an immunosuppressant or applying a topical corticosteroid to the
             affected area

         16. Unwilling to minimize exposure to sunlight and sunlamps during the course of the
             study.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Fabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabella Guiha Schulmann Billings</last_name>
    <phone>858 657 1004</phone>
    <email>iguiha@clderm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Aguilar</last_name>
    <phone>858 657 2004</phone>
    <email>LAguilar@CLDerm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin</keyword>
  <keyword>Chest</keyword>
  <keyword>Photodamage</keyword>
  <keyword>Sun Damage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

